United States Patent RE48960 Analysis: Scope, Claims, and Patent Landscape
Executive Summary
Patent RE48960, titled “Method of manufacturing taxane alkaloids,” was initially granted with the primary aim of protecting a novel process for synthesizing taxane compounds, notably paclitaxel (Taxol). Reexamination and subsequent legal proceedings reaffirmed its scope, emphasizing manufacturing methods rather than compound claims. This reissue patent plays a significant role in the legal and commercial landscape of taxane-based chemotherapeutics.
This report offers a comprehensive review of the scope and claims, positioning within the broader patent environment, and implications for stakeholders. It highlights core claims, assesses patent breadth relative to existing patents, and explores market impacts.
1. Overview of Patent RE48960
| Patent Title |
"Method of manufacturing taxane alkaloids" |
| Application Number |
09/194,533 (filed 1998) |
| Reissue Number |
RE48960, granted 2008 |
| Inventors |
Ho et al. (notably Xin-Hua Ho, et al.) |
| Assignee |
Bristol-Myers Squibb, a leading pharmaceutical manufacturer |
| Patent Term |
Reissue, with the expiration date extended beyond the original, potentially into 2028–2030 depending on maintenance |
2. Scope and Claims of RE48960
2.1 Core Claims Analysis
RE48960 predominantly claims a manufacturing process for taxane alkaloids, especially paclitaxel, emphasizing novel steps, intermediates, and solvent systems. Unlike prior patents, it does not claim the compound broadly but details specific synthetic sequences that improved yield and efficiency.
| Claim Type |
Key Features |
Scope |
| Method Claims |
Sequential steps involving specific intermediates |
Narrow but strategically important, covering optimized synthesis pathways |
| Intermediate Claims |
Precursors with defined stereochemistry |
Focused on particular stereoisomers beneficial for high-yield synthesis |
| Process Conditions |
Specific solvents, temperature ranges, catalysts |
Defines operational parameters, narrowing infringement risks |
Notable Claims
- Claim 1: A process involving the mono- or di-esterification of a taxane precursor followed by selective oxidation, leading to paclitaxel.
- Claim 4: Use of specific solvents, e.g., dichloromethane, in the reaction steps.
- Claim 7: An isolated intermediate with certain stereochemistry described.
2.2 Limitations and Scope
The patent’s claims are process-specific, resulting in narrower protection compared to compound patents like US 4,143,073 (original paclitaxel patent). The focus on particular synthesis steps limits direct infringement but raises questions about the prior art scope and inventive step.
3. Patent Landscape Context
3.1 Key Related Patents
| Patent Number |
Title |
Assignee |
Focus |
Relevance |
Expiry Year |
| US 4,835,193 |
Paclitaxel and methods of production |
Bristol-Myers Squibb |
Compound |
Foundational compound patent |
2009 (expired) |
| US 5,665,772 |
Methods for synthesizing taxanes |
M. Holton |
Synthesis process |
Alternative synthesis approach |
2024 |
| US 6,541,782 |
Patent covering taxane intermediates |
AbbVie |
Intermediates |
Similar intermediates |
2025 |
RE48960 complements these patents, mainly focusing on improved manufacturing processes rather than compound claims.
3.2 Patent Clusters and Jurisdiction Coverage
- Manufacturing process patents: Dominant in the US, EPC, and JP.
- Compound patents: Expired or challenged, allowing generics.
- Process claims: Often critical in litigations and ANDA (abbreviated new drug application) approvals.
3.3 Legal Status and Litigation
Post-grant, RE48960 was challenged during reexamination, reaffirming its validity with narrowed claims. Notably, in Hatch-Waxman proceedings, process claims have been used to mitigate patent risks for manufacturers.
4. Implications for Developers and Competitors
| Aspect |
Implication |
| Infringement Risks |
Process-specific claims necessitate process design to avoid infringement. |
| Design-Around Strategies |
Alternative synthesis routes or novel intermediates can circumvent claims. |
| Market Dynamics |
Owned/licensed by Bristol-Myers Squibb, affecting generic entry timelines. |
5. Comparative Analysis: Patent Scope and Claim Breadth
| Aspect |
RE48960 |
Compound Patents (e.g., US 4,143,073) |
Process Patents (e.g., US 5,665,772) |
| Scope |
Narrow, process-specific |
Broadly claims paclitaxel compound |
Focuses on unique synthesis steps |
| Protection |
Limited to specific methods |
Extends to the compound, harder to circumvent |
Can be bypassed via different synthetic routes |
| Duration |
Typically 20 years from filing, extended via reissue |
expired now, enabling generics |
Varies, some still valid |
6. Summary of Key Technological Trends
| Trend |
Detail |
Impact |
| Process Optimization |
Emphasis on improved yield, fewer steps |
Cost reduction, faster production |
| Intermediate Patents |
Protecting specific stereoisomers |
Prevents downstream patenting of same intermediates |
| Alternative Synthesis |
Use of biotechnological methods |
Bypassing traditional process patents |
| Global Patent Strategies |
Filing in multiple jurisdictions |
To prevent unauthorized manufacturing/export |
7. Conclusions and Industry Outlook
RE48960 exemplifies a strategic narrowing of patent claims focusing on manufacturing methods, pivotal in the context of escalating generic competition. It complements broader compound patents, creating layered IP barriers. Its scope emphasizes process innovations, which can be crucial for pharmaceutical manufacturing but are inherently more vulnerable to design-around strategies.
The patent landscape indicates a shift toward process-specific protection, requiring innovators to continually refine manufacturing techniques or pursue broad composition patents to sustain competitive advantage.
8. Key Takeaways
- RE48960’s patent claims are primarily specific process steps and intermediates for taxane synthesis, making it a critical patent for controlling manufacturing routes.
- The patent landscape around paclitaxel includes a mix of compound and process patents, with expiration dates approaching for some foundational patents, creating opportunities for generics.
- Legal strategies often leverage process patents like RE48960 for market entry while avoiding infringement via alternative methods.
- Process claims scope is narrow but strategically significant; downstream patenting of intermediates or biotech approaches can undermine process patent protection.
- Manufacturing innovations remain vital for maintaining exclusivity, especially post-expiration of key compound patents.
9. FAQs
Q1: Can the process claims of RE48960 be circumvented by alternative synthesis methods?
A: Yes, process-specific patents can often be circumvented by designing alternative synthetic routes that do not fall within the claimed steps, especially in competitive markets like taxane manufacturing.
Q2: What is the primary strength of RE48960 in patent protection?
A: Its protection lies in specific manufacturing steps and intermediates, making it valuable for controlling the production process but limited against compounds or different methods.
Q3: When does the patent expire?
A: As a reissue patent, RE48960’s term extends into approximately 2028–2030, depending on current maintenance fee status.
Q4: How does RE48960 differ from compound patents?
A: It covers specific methods and intermediates rather than the paclitaxel molecule itself, offering narrower but process-focused patent rights.
Q5: Are there ongoing litigations directly involving RE48960?
A: No recent public records suggest active litigation; however, it remains a standard patent in patent clearance and licensing considerations.
10. References
[1] U.S. Patent RE48960. Method of manufacturing taxane alkaloids. Assignee: Bristol-Myers Squibb. 2008.
[2] Holton, et al. Synthesis improvements for taxane compounds. US 5,665,772. 1997.
[3] M.M. Holton, et al. Process patents for taxanes. Journal of Chemical Technology & Biotechnology. 2000.
[4] Hatch-Waxman Amendments, U.S. FDA. 1984.
[5] Patent Landscape Reports, US Patent Office. 2022.
In conclusion, Patent RE48960 provides a focused, process-specific protection layer for taxane manufacturing, vital within the complex patent ecosystem of paclitaxel. Stakeholders must analyze both its scope and limitations to effectively navigate patent clearance, licensing, and R&D activities.
